ArriVent BioPharma appoints Kristine Peterson to Board of Directors

ArriVent BioPharma, Inc.

Appointment effective April 20, 2024; Peterson to serve as Class III Director until 2027 annual meeting.
Peterson brings over 30 years' experience; former CEO of Valeritas and executive at J&J and Bristol-Myers Squibb.
Receives non‑employee director compensation: annual cash retainer of $45,000 and stock option with $235,000 grant date fair value.
Option vests one year from grant date (April 22, 2024); no related transactions or family relations disclosed.
Board determined she is independent under Nasdaq rules; no committee assignments yet.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kristine Peterson

Director

AVBP · ArriVent BioPharma, Inc.

Effective: 2024-04-20
Filed: April 22, 2024, 7:59 PM ET

On April 20, 2024, the Board of Directors (the “Board”) of ArriVent BioPharma, Inc. (the “Company”) appointed Kristine Peterson to the Board, effective immediately

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kristine Peterson was appointed as Director at ArriVent BioPharma, Inc..

Action: appointed
Role: Director

Exact text from the filing

On April 20, 2024, the Board of Directors (the “Board”) of ArriVent BioPharma, Inc. (the “Company”) appointed Kristine Peterson to the Board, effective immediately

View on SEC.gov

ArriVent BioPharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-049988

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.